Issues of consensus and debate for economic evaluation in rheumatology

Journal of Rheumatology

Volumn 28, Issue 3, 2001, Pages 642-647

  Coyle, D ^a   Welch, V ^a   Shea, B ^a   Gabriel, S ^a   Drummond, M ^a   Tugwell, P ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cost effectiveness analysis; Methodology; Standardization; Survey

Indexed keywords

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH SURVEY; HUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; OUTCOMES RESEARCH; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; STANDARDIZATION;

ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; DATA COLLECTION; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; QUALITY OF LIFE; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 0035089622     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. The Journal's policy on cost-effectiveness analyses
2. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
3. Hormone replacement therapy in a risk-benefit perspective
4. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?
5. Improving the evidence base for economic analysis
6. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens
7. Modelling in economic evaluation: An unavoidable fact of life
8. The problem of protocol driven costs in pharmacoeconomic analysis
9. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone
10. Health-related quality of life in economic evaluations for osteoporosis: Whose values should we use?
11. Guidelines for authors and peer reviewers of economic submissions to the BMJ
12. Discounting in health-care decision-making - Time for a change
13. Discounting and health benefits: Another perspective
14. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: An issue for debate?
15. Discounting and health benefits
16. Assessing the economic value of anti-hypertensive medicines
17. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis
18. Common errors and controversies in pharmacoeconomic analyses